Ocak S, et al. (2010) DNA copy number aberrations in small-cell lung cancer reveal activation of the focal adhesion pathway. Oncogene 29, 6331-42 20802517

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

Y397-p - FAK (human) ▲

Modsite: sVsEtDDyAEIIDEE SwissProt Entrez-Gene Orthologous residues FAK (human): Y397‑p, FAK iso2 (human): Y216‑p, FAK iso5 (human): Y397‑p, FAK (mouse): Y397‑p, FAK iso2 (mouse): Y428‑p, FAK iso4 (mouse): Y397‑p, FAK iso9 (mouse): ‑, FAK (rat): Y397‑p, FAK (chicken): Y397‑p, FAK iso5 (chicken): ‑ Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  lung cancer, small-cell lung cancer Relevant cell lines - cell types - tissues:  NCI-H209 (pulmonary), NCI-H69 (pulmonary), NCI-H82 (pulmonary) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes PF-573228 decrease in SCLC cell lines, decrease shown by western blot and immuno¿uorescence staining

Y576-p - FAK (human) ▲

Modsite: RyMEDstyyKAsKGK SwissProt Entrez-Gene Orthologous residues FAK (human): Y576‑p, FAK iso2 (human): Y424‑p, FAK iso5 (human): Y576‑p, FAK (mouse): Y576‑p, FAK iso2 (mouse): Y607‑p, FAK iso4 (mouse): Y576‑p, FAK iso9 (mouse): ‑, FAK (rat): Y576‑p, FAK (chicken): Y576‑p, FAK iso5 (chicken): ‑ Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  lung cancer, small-cell lung cancer Relevant cell lines - cell types - tissues:  NCI-H209 (pulmonary), NCI-H69 (pulmonary), NCI-H82 (pulmonary) Cellular systems studied:  cell lines Species studied:  human

Y165-p - P130Cas (human) ▲

Modsite: PSPATDLyQVPPGPG SwissProt Entrez-Gene Orthologous residues P130Cas (human): Y165‑p, P130Cas iso2 (human): Y183‑p, P130Cas iso6 (human): Y211‑p, P130Cas iso7 (human): Y183‑p, P130Cas iso8 (human): Y165‑p, P130Cas (mouse): Y169‑p, P130Cas (rat): Y263‑p, P130Cas iso2 (rat): Y169‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  lung cancer, small-cell lung cancer Relevant cell lines - cell types - tissues:  NCI-H209 (pulmonary), NCI-H69 (pulmonary), NCI-H82 (pulmonary) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes PF-573228 decrease in SCLC cell lines, decrease shown by western blot and immuno¿uorescence staining